Hepatitis B

Senegal: Hepatitis B - a Silent Emergency in Senegal

More than two million people in Senegal, or some 15 percent of the population, including 350,000 chronic carriers, have hepatitis B as a result of untimely vaccinations, prohibitive treatment costs and lack of universal screening to curb transmissions.
"It's quite an urgent public health concern," said Mamadou Mourtalla Ka, dean of the Thies School of Medicine in Senegal and a viral hepatitis and liver cancer researcher. "Hepatitis B is much more common than people think and causes many illnesses, many deaths here each year."

Shantha’s Pentavalent Pediatric Vaccine prequalified by World Health Organization

Sanofi Pasteur, the vaccines division of Sanofi, announced today that its pediatric pentavalent vaccine Shan5(TM), developed and manufactured by its affiliate Shantha Biotechnics in Hyderabad, India, has received prequalification status from the World Health Organization (WHO). This status is based on a review of a comprehensive set of data related to the process and the product characteristics, as well as on a positive recommendation of WHO’s auditors following a site inspection of Shantha’s manufacturing facilities.

Vaccinating Children Beyond the ‘Cold Chain’: Extending the Heat Stability of Vaccines

Shipping and storing vaccines in a ‘cold chain’ in the tropical heat of many resource-limited countries – whereby the vaccine is kept at temperatures between 2°C to 8°C from the point of manufacture until reaching the recipient – is a tremendous challenge and a major cause of poor immunisation coverage rates.

Congo-Brazzaville: Semaine africaine de vaccination - Les femmes en âge de procréer seront vaccinées contre le tétanos

À l'instar d'autres pays africains, la RDC organise cette semaine de vaccination lancée depuis le 21 avril par le ministre de la Santé publique, le Dr Félix Kabange Numbi, au centre de santé Élonga à Masina.

New vaccine could guard against common birth defect-causing virus

An experimental vaccine using a novel defense mechanism may eventually help protect people from a common virus that affects more than half of the U.S. population and causes congenital birth defects in some cases.
Using the most common form of white blood cell, called neutrophils, scientists from Cardiff University have found a way to quell cytomegalovirus, or CMV.

Public health: Joint purchasing of vaccines and medicines becomes a reality in the EU

Today, the Commission approved a Joint Procurement Agreement, which will enable all EU countries to procure pandemic vaccines and other medical countermeasures as a group, rather than individually.

Immunize Canada announces the new ImmunizeCA App

Visit Immunize Canada about the ImmunizeCA appFrom Immunize Canada's website:

ImmunizeCA App

What it does

Provide Canadians with the ability to:



This year, the doctors are going to provide coverage of at least 97% of a contingent with preventive vaccinations, according to the national immunization schedule. This will ensure the country's epidemiological wellbeing on infections, the spread of which can be successfully controlled through vaccination.

Read more.


Millions of Nigeria children in danger as country runs out of vaccines

An estimated six to seven million Nigerian children of immunizable age are in danger of dying from vaccine-preventable diseases this year, if the Federal Government fails to intervene in the current stock out of vaccines in the country, a body of scientists is warning.
The impact may not be fully felt yet as some states still rely on reserves. Lagos State, for instance, says it still has a three-month supply of BCG (given at birth against tuberculosis) OPV (oral polio virus), Pentavalent combination, measles, yellow fever and tetanus toxoid vaccines).

Virus-like particles (VLPs) as vaccines, vectors and adjuvants Conference

Hosted by Fondation-Merieux.

From the Fondation-Merieux website: 

Vaccines are playing a major role in reducing the impact of infectious diseases. Nevertheless, vaccines have still to target important health problems. The development of individual viral proteins as vaccine candidates has met a limited success although these viral proteins were the targets of neutralizing antibodies mediating protection.

Alternative approaches are needed, and virus-like particles (VLPs) could contribute to progress in this regard.